The Sonic Fund II, L.P. Issues Presentation Detailing Compelling Case for Immediate Board Upgrade at Adverum Biotechnologies, Inc.

The investor presentation is available at: www.SaveAdverum.com.

Highlights include the following:

• Adverum has grossly mismanaged the drug development process and is doing a grave disservice to stockholders and suffering patients
  • Adverum has severely mismanaged the scientific development of ADVM-022, its gene therapy treatment for wet AMD, by failing to adequately address the ocular inflammation issue it has posed
  • The Company’s intense focus on commercialization efforts seem to ignore the fact that the drug still needs to be approved
  • The Company has repeatedly botched investor communications around its drug development and has demonstrated inept capital allocation ability, including by recklessly approving a badly-timed $200 million secondary offering in August of 2020

• Sonic is NOT seeking control of the Adverum Board – Rather, it is seeking to add independence to an increasingly interconnected set of directors
  • The Company’s own prior disclosure admits the 2019 director choices were mutual
  • Both directors that Sonic identified for the Board in 2019 are fully independent of Sonic and of each other, as proven by the unanimous votes of the sitting Board
  • Mr. Kam did not personally know any of Sonic’s current nominees until two months ago
  • Relying on its extensive network in the gene therapy field, Sonic simply identified highly respected leaders and experts in this sector and managed to interest them in serving on the Adverum Board – these nominees have world-class experience and are the best people for the job
  • Stockholders can see for themselves that the Company has not attracted candidates of the same caliber, although that is precisely the job of the Nominating and Governance Committee

• Adverum’s control argument is merely a smokescreen to distract stockholders from Board Chair Patrick Machado’s efforts to stack the boardroom with his cronies
  • We believe that Adverum will have to expand the Board to 11 seats by the end of 2021 to add the required proportion of female directors to comply with Sections 301.3 and 2115.5 of the California Corporations Code (implementing SB 826) (“SB 826”), the California Board gender diversity law
  • Therefore, even if one were to concede their argument – which Sonic does not – that any director suggested or nominated by Sonic would become part of a block, it is impossible to argue that five out of 11 directors constitutes control

• The incumbent Board’s entrenchment maneuvers will lead to more of the same and disenfranchise stockholders unless stockholders vote for truly independent directors
  • Rather than considering our nominees in good faith, Adverum instead elected to force a wholly unnecessary proxy contest on an extremely compressed timeline
  • The Board’s inconsistent obfuscations around the size of the class up for election at the 2021 Annual Meeting seem designed to perpetuate the status quo and confuse stockholders
  • Adverum’s intent seems to be to deprive stockholders of the ability to vote on the two additional female directors it will have to add to the Board by the end of 2021

• Board improvement is urgently needed to chart a better course forward and responsibly hold management accountable
  • The status quo is unsustainable – stockholders have lost confidence in a Board that has overseen such drastic value destruction and has not laid out a convincing go-forward strategy to achieve Adverum’s full potential
  • The Company’s director slate lacks necessary experience and is riddled with conflictual relationships
  • Sonic’s nominees are all obviously and objectively better qualified than the Company’s candidates. They are all independent of Sonic and of each other and would bring tremendous gene therapy experience and financial / leadership ability

Vote on the GREEN proxy card today

View source version on businesswire.com: https://www.businesswire.com/news/home/20210422006125/en/